Evidence map›Paper›PMID 41701293›Full record

ArticleMolecular neurobiology2026

Single-Cell RNA Sequencing Reveals Impaired CHIP-Mediated Heat Stress Response in SCA3 Pathogenesis.

Mi-Bo Tang, Shi-Feng Sheng, Zheng-Wei Hu, Hai-Yang Luo, Meng-Jie Li, Shuo Zhang, Xiao-Yan Hao, Cheng-Yuan Mao, Shao-Hua Li, Hui-Fang Sun and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mi-Bo Tang *Department of Geriatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450000, Henan, China. tangmibohappy@126.com.
Shi-Feng Sheng *Health Management Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Zheng-Wei HuDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450000, Henan, China.
Hai-Yang LuoDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450000, Henan, China.
Meng-Jie LiDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450000, Henan, China.
Shuo ZhangDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450000, Henan, China.
Xiao-Yan HaoDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450000, Henan, China.
Cheng-Yuan MaoDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450000, Henan, China.
Shao-Hua LiDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450000, Henan, China.
Hui-Fang SunDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450000, Henan, China.
Zhi-Hua YangDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450000, Henan, China.
Yi SongDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Chang-He ShiDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450000, Henan, China. shichanghe@gmail.com.
Yu-Ming XuDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450000, Henan, China. xuyuming@zzu.edu.cn.

Funding

China Postdoctoral Science Foundation 2025M782273Henan Province Key Scientific Research Projects of Universitiesty 23A320023Henan Provincial Science and Technology Research Project LHGJ 20210296Henan Provincial Science and Technology Research Project LHGJ20230200National Natural Science Foundation of China 82101491
6 · The paper itself

Abstract

Nine distinct polyglutamine (PolyQ) diseases are caused by CAG repeat expansions in the coding regions of their respective causative genes, among which spinocerebellar ataxia type 3 (SCA3), driven by CAG repeat expansion in the ATXN3 gene, is one of the most common subtypes. SCA3 is characterized by the aggregation of mutant Ataxin-3 (containing an expanded polyglutamine tract, encoded by ATXN3) into neuronal intranuclear inclusions, leading to progressive neurodegeneration. Despite extensive research, the precise molecular mechanisms underlying mutant Ataxin-3-induced neurotoxicity remain elusive, and there is still a lack of effective therapeutic strategies for SCA3. To address these gaps, the present study aimed to elucidate the key pathophysiological cascades driving SCA3 progression and identify potential therapeutic targets by investigating cellular and molecular alterations in SCA3 models. Our results showed that SCA3 cells exhibited significantly reduced viability and increased thermolability. In SCA3 transgenic mice, a large portion of the C terminus of Hsc70-interacting protein (CHIP) was sequestered within neuronal intranuclear inclusions, resulting in a progressive, age-dependent decline in soluble CHIP level. Single-Cell RNA Sequencing (ScRNA-seq) analysis of the cerebellum from these mice revealed dysregulated cellular stress response in SCA3. Native gel electrophoresis revealed that the level of trimerized HSF1 in SCA3 cells was significantly lower than that in wild-type cells, indicating that stress intolerance may be involved in the pathogenesis of SCA3. This further validated and specified results of ScRNA-Seq. Importantly, overexpression of CHIP partially restored HSF1 function, rescued DNAJB1 (homolog of HSP40) and the defective heat stress response, and ameliorated multiple disease-related phenotypes in SCA3 models. This further reveals that the reduction in functional CHIP caused by Ataxin3 mutation may represent an upstream event responsible for stress intolerance in SCA3. Collectively, our findings demonstrate that depletion of soluble CHIP promotes SCA3 progression by disrupting the CHIP-HSF1/DNAJB1 axis. This work not only clarifies a critical pathogenic mechanism of SCA3 but also underscores the therapeutic potential of modulating CHIP activity as a novel intervention strategy for SCA3. These results provide a clearer contextual framework for understanding SCA3 pathogenesis and lay a foundation for the development of targeted therapies.

Indexed as

Heat-Shock ResponseMachado-Joseph DiseaseSequence Analysis, RNASingle-Cell AnalysisAnimalsAtaxin-3HumansMice, TransgenicSingle-Cell Gene Expression AnalysisAtaxin-3CHIPHeat shock stressHSF1SCA3Single-cell RNA sequencing

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.